Boehringer Ingelheim Presents New Data for Pradaxa® and its Specific Reversal Agent Idarucizumab (Praxbind®) at AHA Scientific Sessions 2017

RIDGEFIELD, Conn., Nov. 10, 2017 /PRNewswire/ -- Boehringer Ingelheim today announced that important sub-analyses from three major trials in anticoagulation care will be presented at the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, California, November 11-15. In...